5,998
Views
45
CrossRef citations to date
0
Altmetric
Review Article

Bile salts-containing vesicles: promising pharmaceutical carriers for oral delivery of poorly water-soluble drugs and peptide/protein-based therapeutics or vaccines

Pages 1847-1867 | Received 24 Sep 2014, Accepted 11 Oct 2014, Published online: 12 Nov 2014

References

  • Andrieux K, Forte L, Lesieur S, et al. (2009). Solubilisation of dipalmitoylphosphatidylcholine bilayers by sodium taurocholate: a model to study the stability of liposomes in the gastrointestinal tract and their mechanism of interaction with a model bile salt. Eur J Pharm Biopharm 71:346–55
  • Aramaki Y, Tomizawa H, Hara T, et al. (1993). Stability of liposomes in vitro and their uptake by rat Peyer’s patches following oral administration. Pharm Res 10:1228–31
  • Beg S, Samad A, Nazish I, et al. (2013). Colloidal drug delivery systems in vaccine delivery. Curr Drug Targets 14:123–37
  • Boyd BJ. (2008). Past and future evolution in colloidal drug delivery systems. Expert Opin Drug Deliv 5:69–85
  • Bragagni M, Mennini N, Maestrelli F, et al. (2012). Comparative study of liposomes, transfersomes and ethosomes as carriers for improving topical delivery of celecoxib. Drug Deliv 19:354–61
  • Bramwell VW, Perrie Y. (2006). Particulate delivery systems for vaccines: what can we expect? J Pharm Pharmacol 58:717–28
  • Chavanpatil MD, Vavia PR. (2005). Nasal drug delivery of sumatriptan succinate. Pharmazie 60:347–9
  • Chen Y, Lu Y, Chen J, et al. (2009). Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt. Int J Pharm 376:153–60
  • Chiang CH, Lai JS, Yang KH. (1991). The effect of pH and chemical enhancers on the percutaneous absorption of indomethacin. Drug Dev Ind Pharm 17:91–111
  • Conacher M, Alexander J, Brewer JM. (2001). Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine 19:2965–74
  • Dai Y, Zhou R, Liu L, et al. (2013). Liposomes containing bile salts as novel ocular delivery systems for tacrolimus (FK506): in vitro characterization and improved corneal permeation. Int J Nanomedicine 8:1921–33
  • Demetzos C, Pippa N. (2014). Advanced drug delivery nanosystems (aDDnSs): a mini-review. Drug Deliv 21:250–7
  • Deneer VH, Drese GB, Roemelé PE, et al. (2002). Buccal transport of flecainide and sotalol: effect of a bile salt and ionization state. Int J Pharm 241:127–34
  • Dertzbaugh MT, Elson CO. (1993). Comparative effectiveness of the cholera toxin B subunit and alkaline phosphatase as carriers for oral vaccines. Infect Immun 61:48–55
  • Dial EJ, Rooijakkers SH, Darling RL, et al. (2008). Role of phosphatidylcholine saturation in preventing bile salt toxicity to gastrointestinal epithelia and membranes. J Gastroenterol Hepatol 23:430–6
  • Duchateau GSMJE, Zuidema J, Merkus FWHM. (1986). Bile salts and intranasal drug absorption. Int J Pharm 31:193–9
  • Eldridge JH, Hammond CJ, Meulbroek JA, et al. (1990). Controlled vaccine release in the gut-associated lymphoid tissues. 1 Orally administered biodegradable microspheres target the Peyer’s patches. J Control Release 11:205–14
  • Gangadhar KN, Adhikari K, Srichana T. (2014). Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation. Int J Pharm 471:430–8
  • Gaspar MM, Martins MB, Corvo ML, Cruz ME. (2003). Design and characterization of enzymosomes with surface-exposed superoxide dismutase. Biochim Biophys Acta 1609:211–17
  • Gaumet M, Gurny R, Delie F. (2009). Localization and quantification of biodegrad-able particles in an intestinal cell model: the influence of particle size. Eur J Pharm Sci 36:465–73
  • Gebril AM, Lamprou DA, Alsaadi MM, et al. (2014). Assessment of the antigen-specific antibody response induced by mucosal administration of a GnRH conjugate entrapped in lipid nanoparticles. Nanomedicine 10:971–9
  • Guan P, Lu Y, Qi J, et al. (2011). Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt. Int J Nanomedicine 6:965–74
  • Guo J, Wu T, Ping Q, et al. (2005). Solubilization and pharmacokinetic behaviors of sodium cholate/lecithin-mixed micelles containing cyclosporine A. Drug Deliv 12:35–9
  • Gupta S, Jain A, Chakraborty M, et al. (2013). Oral delivery of therapeutic proteins and peptides: a review on recent developments. Drug Deliv 20:237–46
  • Henriksen-Lacey M, Perrie Y. (2013). Designing liposomes as vaccine adjuvants. In: Flower DR, Perrie Y, eds. Immunomic discovery of adjuvants and candidate subunit vaccines. New York: Springer, Chapter 10, 181–203
  • Hofmann AF, Hagey LR. (2008). Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci 65:2461–83
  • Holm R, Müllertz A, Mu H. (2013). Bile salts and their importance for drug absorption. Int J Pharm 453:44–55
  • Honeywell-Nguyen PL, Bouwstra JA. (2005). Vesicles as a tool for transdermal and dermal delivery. Drug Discov Today Technol 2:67–74
  • Hu S, Niu M, Hu F, et al. (2013). Integrity and stability of oral liposomes containing bile salts studied in simulated and ex vivo gastrointestinal media. Int J Pharm 441:693–700
  • Immordino ML, Dosio F, Cattel L. (2006). Stealth liposomes: review of the basic science, rationale, and clinicl applications, existing and potential. Int J Nanomedicine 1:297–315
  • Jain S, Harde H, Indulkar A, Agrawal AK. (2014a). Improved stability and immunological potential of tetanus toxoid containing surface engineered bilosomes following oral administration. Nanomedicine 10:431–40
  • Jain S, Indulkar A, Harde H, Agrawal AK. (2014b). Oral mucosal immunization using glucomannosylated bilosomes. J Biomed Nanotechnol 10:932–47
  • Jain S, Khomane K, K Jain A, Dani P. (2011). Nanocarriers for transmucosal vaccine delivery. Curr Nanoscience 7:160–77
  • Kowapradit J, Apirakaramwong A, Ngawhirunpat T, et al. (2012). Methylated N-(4-N,N-dimethylaminobenzyl) chitosan coated liposomes for oral protein drug delivery. Eur J Pharm Sci 47:359–66
  • Le Dévédec F, Strandman S, Hildgen P, et al. (2013). PEGylated bile acids for use in drug delivery systems: enhanced solubility and bioavailability of itraconazole. Mol Pharm 10:3057–66
  • Li P, Nielsen HM, Müllertz A. (2012). Oral delivery of peptides and proteins using lipid-based drug delivery systems. Expert Opin Drug Deliv 9:1289–304
  • Liu J, Gong T, Wang C, et al. (2007). Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization. Int J Pharm 340:153–62
  • Mahalingam R, Ravivarapu H, Redkar S, et al. (2007). Transbuccal delivery of 5-aza-2 -deoxycytidine: effects of drug concentration, buffer solution, and bile salts on permeation. AAPS PharmSciTech 13;8:E55
  • Malik DK, Baboota S, Ahuja A, et al. (2007). Recent advances in protein and peptide drug delivery systems. Curr Drug Deliv 4:141–51
  • Mann JF, Scales HE, Shakir E, et al. (2006). Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity. Methods 38:90–5
  • Mann JF, Shakir E, Carter KC, et al. (2009). Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection. Vaccine 27:3643–9
  • Martin SR, Schilstra MJ. (2008). Circular dichroism and its application to the study of biomolecules. Methods Cell Biol 84:263–93
  • Martins S, Sarmento B, Ferreira DC, Souto EB. (2007). Lipid-based colloidal carriers for peptide and protein delivery-liposomes versus lipid nanoparticles. Int J Nanomedicine 2:595–607
  • McGhee JR, Mestecky J, Dertzbaugh MT, et al. (1992). The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 10:75–88
  • Mikov M, Fawcett JP, Kuhajda K, Kevresan S. (2006). Pharmacology of bile acids and their derivatives: absorption promoters and therapeutic agents. Eur J Drug Metab Pharmacokinet 31:237–51
  • Miyazaki S, Yamahira T, Nadai T. (1981). Effect of bile flow on indomethacin absorption in rats. Acta Pharm Suec 18:135–8
  • Morimoto K, Nakai T, Morisaka K. (1987). Evaluation of permeability enhancement of hydrophilic compounds and macromolecular compounds by bile salts through rabbit corneas in vitro. J Pharm Pharmacol 39:124–6
  • Neutra MR, Kozlowski PA. (2006). Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6:148–58
  • Nguyen S, Alund SJ, Hiorth M, et al. (2011). Studies on pectin coating of liposomes for drug delivery. Colloids Surf B Biointerfaces 88:664–73
  • Nightingale CH, Axelson JE, Gibaldi M. (1971). Physiologic surface-active agents and drug absorption. 8. Effect of bile flow on sulfadiazine absorption in the rat. J Pharm Sci 60:145–7
  • Niu M, Lu Y, Hovgaard L, et al. (2012). Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose. Eur J Pharm Biopharm 81:265–72
  • Niu M, Lu Y, Hovgaard L, Wu W. (2011). Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation. Int J Nanomedicine 6:1155–66
  • Niu M, Tan Y, Guan P, et al. (2014). Enhanced oral absorption of insulin-loaded liposomes containing bile salts: a mechanistic study. Int J Pharm 460:119–30
  • Ogiso T, Iwaki M, Yoneda I, et al. (1991). Percutaneous absorption of elcatonin and hypocalcemic effect in rat. Chem Pharm Bull 39:449–53
  • O'Reilly JR, Corrigan OI, O'Driscoll CM. (1994). The effect of mixed micellar systems, bile salt/fatty acids, on the solubility and intestinal absorption of clofazimine (B663) in the anaesthetised rat. Int J Pharm 109:147–54
  • Parmentier J, Thewes B, Gropp F, Fricker G. (2011). Oral peptide delivery by tetraether lipid liposomes. Int J Pharm 415:150–7
  • Pandey V, Golhani D, Shukla R. (2014). Ethosomes: versatile vesicular carriers for efficient transdermal delivery of therapeutic agents. Drug Deliv. [Epub ahead of print]
  • Premanand B, Prabakaran M, Kiener TK, Kwang J. (2013). Recombinant baculovirus associated with bilosomes as an oral vaccine candidate against HEV71 infection in mice. PLoS One 8:e55536
  • Pütz G, Schmider W, Nitschke R, et al. (2005). Synthesis of phospholipid-conjugated bile salts and interaction of bile salt-coated liposomes with cultured hepatocytes. J Lipid Res 46:2325–38
  • Rath A, Glibowicka M, Nadeau VG, et al. (2009). Detergent binding explains anomalous SDS-PAGE migration of membrane proteins. Proc Natl Acad Sci USA 106:1760–5
  • Saettone MF, Chetoni P, Cerbai R, et al. (1996). Evaluation of ocular permeation enhancers: in vitro effects on corneal transport of four β-blockers, and in vitro/in vivo toxic activity. Int J Pharm 142:103–13
  • Sahdev P, Ochyl LJ, Moon JJ. (2014). Biomaterials for nanoparticle vaccine delivery systems. Pharm Res 31:2563–82
  • Samstein RM, Perica K, Balderrama F, et al. (2008). The use of deoxycholic acid to enhance the oral bioavailability of biodegradable nanoparticles. Biomaterials 29:703–8
  • Schubert R, Jaroni H, Schoelmerich J, Schmidt KH. (1983). Studies on the mechanism of bile salt-induced liposomal membrane damage. Digestion 28:181–90
  • Semalty A, Semalty M, Rawat BS, et al. (2009). Pharmacosomes: the lipid-based new drug delivery system. Expert Opin Drug Deliv 6:599–612
  • Shao Z, Mitra AK. (1994). Bile salt-fatty acid mixed micelles as nasal absorption promoters. III. Effects on nasal transport and enzymatic degradation of acyclovir prodrugs. Pharm Res 11:243–50
  • Shukla A, Katare OP, Singh B, Vyas SP. (2010a). M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes. Int J Pharm 385:47–52
  • Shukla A, Bhatia A, Amarji B, et al. (2010b). Nano-bilosomes as potential vaccine delivery system for effective combined oral immunization against tetanus and hepatitis B. J Biotech 150:98–9
  • Shukla A, Khatri K, Gupta PN, et al. (2008). Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes). J Pharm Pharm Sci 11:59–66
  • Shukla A, Singh B, Katare OP. (2011). Significant systemic and mucosal immune response induced on oral delivery of diphtheria toxoid using nano-bilosomes. Br J Pharmacol 164:820–7
  • Singh P, Prabakaran D, Jain S, et al. (2004). Cholera toxin B subunit conjugated bile salt stabilized vesicles (bilosomes) for oral immunization. Int J Pharm 278:379–90
  • Sinico C, Fadda AM. (2009). Vesicular carriers for dermal drug delivery. Expert Opin Drug Deliv 6:813–25
  • Song KH, Chung SJ, Shim CK. (2005). Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts. J Control Release 106:298–308
  • Subuddhi U, Mishra AK. (2007). Effect of sodium deoxycholate and sodium cholate on DPPC vesicles: a fluorescence anisotropy study with diphenylhexatriene. J Chem Sci 119:169–74
  • Sun J, Deng Y, Wang S, et al. (2010). Liposomes incorporating sodium deoxycholate for hexamethylmelamine (HMM) oral delivery: development, characterization, and in vivo evaluation. Drug Deliv 17:164–70
  • Sun W, Zou W, Huang G, et al. (2008). Pharmacokinetics and targeting property of TFu-loaded liposomes with different sizes after intravenous and oral administration. J Drug Target 16:357–65
  • Tengamnuay P, Mitra AK. (1990). Bile salt-fatty acid mixed micelles as nasal absorption promoters of peptides. II. In vivo nasal absorption of insulin in rats and effects of mixed micelles on the morphological integrity of the nasal mucosa. Pharm Res 7:370–5
  • Tiwari SB, Amiji MM. (2006). Improved oral delivery of paclitaxel following administration in nanoemulsion formulations. J Nanosci Nanotechnol 6:3215–21
  • Tiwari AK, Gajbhiye V, Sharma R, Jain NK. (2010). Carrier mediated protein and peptide stabilization. Drug Deliv 17:605–16
  • Torchilin VP. (2005). Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145–60
  • Vyas SP, Subhedar R, Jain S. (2006). Development and characterization of emulsomes for sustained and targeted delivery of an antiviral agent to liver. J Pharm Pharmacol 58:321–6
  • Ward PD, Tippin TK, Thakker DR. (2000). Enhancing paracellular permeability by modulating epithelial tight junctions. Pharm Sci Technol Today 3:346–58
  • Westergaard H. (1977). Duodenal bile acid concentrations in fat malabsorption syndromes. Scand J Gastroent 12:115–22
  • Wilkhu JS, McNeil SE, Anderson DE, Perrie Y. (2013). Characterization and optimization of bilosomes for oral vaccine delivery. J Drug Target 21:291–9
  • Yu JN, Zhu Y, Wang L, et al. (2010). Enhancement of oral bioavailability of the poorly water-soluble drug silybin by sodium cholate/phospholipid-mixed micelles. Acta Pharmacol Sin 31:759–64
  • Zeng X, Tao W, Mei L, et al. (2013). Cholic acid-functionalized nanoparticles of star-shaped PLGA-vitamin E TPGS copolymer for docetaxel delivery to cervical cancer. Biomaterials 34:6058–67
  • Zhang Z, Gao F, Jiang S, et al. (2013). Bile salts enhance the intestinal absorption of lipophilic drug loaded lipid nanocarriers: mechanism and effect in rats. Int J Pharm 452:374–81

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.